跳至主要内容
临床试验/NCT06882096
NCT06882096招募中1 期

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors in Healthy Young and Older Adults

Metro International Biotech, LLC1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2025年4月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
32
试验地点
1
主要终点
Labelled NAD+ in Peripheral Blood

研究概览

简要总结

We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.

Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease

What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.

Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.

Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.

A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.

Possible benefits and risks:

Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.

NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.

Researchers will monitor participants closely for any side effects throughout the study.

详细描述

Background and Significance

1.1 Role of NAD+ in Physiology Nicotinamide adenine dinucleotide (NAD+) is a key coenzyme in all living organisms, existing in oxidized (NAD+) and reduced (NADH) forms. Beyond its vital role in redox reactions and ATP generation, NAD+ also serves as a co-substrate for several signaling enzymes such as sirtuins, PARPs, and CD38. Systemic NAD+ insufficiency can cause diseases like pellagra; reduced NAD+ availability has been implicated in aging and age-related disorders.

1.2 Oral NAD+ Precursors Administration of NAD+ precursors (e.g., NMN, NR, NAM) can boost NAD+ levels. Although human research has shown that oral NMN raises blood NAD+ concentrations, many aspects of its absorption, metabolism, and overall bioavailability are still poorly understood. Rodent studies suggest oral NMN undergoes extensive first-pass metabolism in the gut, with partial conversion to NAM prior to entering systemic circulation.

1.3 Aging and NAD+ In rodent models, NAD+ levels frequently decline as the animals get older. Some evidence indicates that NAD+ turnover may be elevated in aging rodents, suggesting a higher rate of NAD+ consumption. However, equivalent tracer studies have not yet been conducted in humans.

1.4 Need for Human Tracer Studies These compounds are being investigated for the prevention and treatment of age-related diseases. There is a need to clarify how they are absorbed and how exactly they elevate NAD+ in different tissues. Using stable isotope-labeled NMN and NAM will help map the flux from oral precursors into blood, muscle, urine, and stool, and will also reveal how aging influences NAD+ turnover.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

NMN- Nicotinamide Mononucleotide

Active Comparator

This arm will include 16 participants (8 young and 8 older adults) who will receive NMN once daily for 14 consecutive days.

干预措施: Nicotinamide Mononucleotide (NMN) (Drug)

NAM- Nicotinamide

Active Comparator

This arm will include 16 participants (8 young and 8 older adults) who will receive NAM once daily for 14 consecutive days.

干预措施: Nicotinamide (NAM) (Drug)

结局指标

主要结局

Labelled NAD+ in Peripheral Blood

时间窗: During the Study Intervention Period Day 1 through Day 14

Quantify the fraction of peripheral blood. NAD+ containing the stable isotope labelled tracer

次要结局

  • Labelled NAD+ in Muscle(During the Study Intervention Period Day 1 through Day 14)
  • N-methyl-2-pyridone-5-carboxamide (2PY) in Muscle(During the Study Intervention Period Day 1 through Day 14)
  • N-methyl-2-pyridone-5-carboxamide (2PY) in Stool(During the Study Intervention Period Day 1 through Day 14)
  • 1-Methyl nicotinamide (MeNAM) in Plasma(During the Study Intervention Period Day 1 through Day 14)
  • 1-Methyl nicotinamide (MeNAM) in Muscle(During the Study Intervention Period Day 1 through Day 14)
  • Nicotinamide in Plasma(During the Study Intervention Period Day 1 through Day 14)
  • 1-Methyl nicotinamide (MeNAM) in Urine(During the Study Intervention Period Day 1 through Day 14)
  • 1-Methyl nicotinamide (MeNAM) in Stool(During the Study Intervention Period Day 1 through Day 14)
  • N-methyl-2-pyridone-5-carboxamide (2PY) in Plasma(During the Study Intervention Period Day 1 through Day 14)
  • Nicotinamide in Urine(During the Study Intervention Period Day 1 through Day 14)
  • N-methyl-2-pyridone-5-carboxamide (2PY) in Urine(During the Study Intervention Period Day 1 through Day 14)
  • Nicotinamide in Muscle(During the Study Intervention Period Day 1 through Day 14)
  • Nicotinamide in Stool(During the Study Intervention Period Day 1 through Day 14)

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Shalender Bhasin

Principal Investigator

Metro International Biotech, LLC

研究点 (1)

Loading locations...

相似试验